SVE.WAR Synthaverse S.A.

Healthcare Biotechnology Warsaw Stock Exchange
2.65 PLN
Close of Oct 29, 2026
2.64 4.22
Market cap
PLN 201M
P/E
-
P/B
1.73x
ROE
-10.7%
Dividend yield
-
Fundamental score
1.1/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is SVE.WAR undervalued?

Graham number

The Graham number of Synthaverse S.A. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Synthaverse S.A. fundamental analysis

5 of 21 checks passed

ROE 0/2

Low return on equity (-10.7%), below 10%.

ROA 1/1

Return on assets (-4.3%) is above the industry median (-18.6%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share did not grow over the past 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 0/1

Last year's EPS growth (-356.6%) is below the industry median (2.6%).

Revenue Growth 0/2

Revenue shrank 5.9% a year over the past 3 years.

Short-term Liquidity 0/1

Current assets do not cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 1/2

Moderate debt to equity (76.5%), up to 100%.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Cash Runway 2/2

Loss-making but free cash flow is positive.

PE vs Market 0/1

PE is negative or not available.

PE vs Industry 0/1

PE is negative or not available.

PBV 1/1

Price to book (1.7x) is below the industry median (3.6x).

Graham Number 0/1

Graham number needs positive earnings and book value.

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Synthaverse S.A. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Synthaverse S.A.

Synthaverse S.A., a pharmaceutical company, manufactures and sells medicinal preparations, medical devices, and laboratory reagents for use in oncology, gynecology, hematology, immunology, and related therapeutic areas in Poland, the rest of the European Union, and internationally. The company operates through the BCG and Traditional segments. The company offers OnkoBCG 50 and 100, which are oncological immunotherapy products used to treat superficial and non-invasive bladde…

Full company profile